Thyrotropin Alfa
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Thyrotropin alfa: From Thyroid Cancer Follow-up to Migraine Disorder
One-Sentence Summary
Thyrotropin alfa is a recombinant human thyroid-stimulating hormone (TSH) generally used as a diagnostic and therapeutic adjunct in the follow-up of differentiated thyroid cancer. The TxGNN model predicts it may be effective for Migraine Disorder, but this ranking is currently supported by 0 clinical trials and 0 publications, and the evidence pack itself notes no known biological mechanism connecting TSH receptor activation to migraine pathophysiology.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Diagnostic/therapeutic adjunct in differentiated thyroid cancer follow-up (based on general pharmacological knowledge of thyrotropin alfa; no formal EU license text is available in the Evidence Pack) |
| Predicted New Indication | Migraine Disorder |
| TxGNN Prediction Score | 99.98% |
| Evidence Level | L5 |
| EU Market Status | ✗ Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the Evidence Pack. Based on general pharmacological knowledge, thyrotropin alfa is a recombinant form of human TSH that binds to and activates the TSH receptor on thyroid follicular cells, stimulating iodine uptake and thyroglobulin release; it is typically used to enhance the sensitivity of diagnostic and ablative procedures in thyroid cancer management.
For the top-ranked prediction, migraine disorder, the Evidence Pack’s own mechanistic assessment is explicit and unfavorable: there is no known interaction between TSH receptor activation and the pathways implicated in migraine (trigeminovascular system, CGRP signaling). This appears to be a pure knowledge-graph pattern-based prediction rather than one grounded in an established or plausible biological mechanism, and it is not corroborated by any clinical trial or literature evidence.
Given the combination of a null mechanistic rationale and a complete absence of supporting clinical or literature evidence, this specific prediction should be treated as low-confidence and exploratory only.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
EU Market Information
No EU marketing authorizations are present in the current dataset — the Evidence Pack records this drug as not marketed (0 licenses).
Safety Considerations
Please refer to the SmPC for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (migraine disorder) has no supporting clinical trials, no supporting literature, and no plausible mechanistic link per the Evidence Pack’s own analysis — it reflects a pure knowledge-graph association. Separately, among the 10 candidate indications in this pack, only hyperthyroidism (rank 10) has actual clinical trial and literature evidence (L2), but that evidence describes TSH used as a pre-treatment sensitizer before radioiodine therapy for benign nodular goiter, not as a treatment for hyperthyroidism itself, and the mechanistic direction is contradictory since a TSH receptor agonist would be expected to stimulate — not suppress — thyroid hormone production. None of the 10 candidates currently justify progression.
To proceed, the following is needed:
- Detailed mechanism of action (MOA) data for thyrotropin alfa (currently a Blocking-severity gap)
- Regulatory label data — warnings, contraindications, and drug interactions (currently a Blocking-severity gap; needed before any S1 safety screening)
- Confirmation of current EU marketing/authorization status, as the Evidence Pack shows the drug as not marketed
- Preclinical or mechanistic studies establishing a biological rationale for TSH pathway involvement in migraine before further clinical evidence is sought
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.